锦衣卫

1至7月河北经济总体平稳 发展向新向优_我的网站

一 |     

在安平县丝网集团共享智造中试工厂，机械臂在进行焊接。    Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。

二 | 马子涵 摄长城网·冀云客户端讯（记者 刘朋朋）8月21日，省统计局发布1至7月份经济运行情况。数据显示，前7个月，全省经济运行呈现总体平稳、向新向优发展态势，新动能加速成长。工业生产运行平稳。1至7月份，全省规模以上工业增加值同比增长5.5%。规模以上工业统计的40个行业大类中，28个行业实现增长，增长面为70.0%。

三 | 其中，仪器仪表制造业增加值增长52.4%，有色金属矿采选业增长23.9%，医药制造业增长12.5%，汽车制造业增长9.7%，铁路船舶航空航天和其他运输设备制造业增长11.8%。

四 | 固定资产投资持续增长。

五 | 1至7月份，全省固定资产投资同比增长0.3%。大项目支撑作用明显，10亿元以上建设项目完成投资增长5.5%，拉动全省投资增长2.3个百分点。工业投资增长6.3%，工业技改投资增长10.1%，分别拉动全省投资增长2.0和1.6个百分点。大规模设备更新政策持续发力显效，设备工器具购置投资增长34.0%。消费品市场规模平稳扩大。1至7月份，全省限额以上单位消费品零售额2944.0亿元，同比增长4.9%。消费品以旧换新政策持续显效，文化办公用品类、家用电器和音像器材类、通讯器材类商品零售额分别增长90.7%、19.8%和16.6%。升级类商品零售回升，化妆品类、体育娱乐用品类、金银珠宝类商品零售额分别增长8.0%、3.9%和2.9%，比上半年加快2.5、3.5和0.5个百分点。

六 | 新动能加快培育壮大。1至7月份，全省规模以上工业战略性新兴产业增加值增长11.1%，快于规模以上工业增速5.6个百分点。

七 | 其中，光电子器件制造增加值增长3.4倍，集成电路制造增长40.2%，高铁车组制造增长23.4%，风能原动设备制造增长13.2%。

八 | 高新技术产业增加值同比增长7.5%，快于规上工业增速2.0个百分点。光电子器件、集成电路、锂离子电池等新产品产量快速增长，分别增长79.7%、57.4%和87.0%。高技术产业投资增长17.3%。

Current article:http://8cu0.feizengbubaipeirangnalouchuo.sbs/list_v32g2/esvlxg6.html

Published on:12:01:54